Pharmaceutical Dextran (glucose) Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Pharmaceutical Dextran (Glucose) Market Report is Segmented by Power Type (Dextran 20, Dextran 40, Dextran 60, Dextran 70, and Other Power Types), Application (Vaccines, Eye Care, Protein Stabilization, Cryopreservation, Oral Application, and Other Applications), and Geography (North America, Europe, Asia-Pacific, and the Rest of the World). The Report Offers the Market Size and Forecasts for the Pharmaceutical Dextran (Glucose) Market in Value (USD) for the Above Segments.

Pharmaceutical Dextran (Glucose) Market Size

Pharmaceutical Dextran (Glucose) Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 231.20 Million
Market Size (2029) USD 292.80 Million
CAGR (2024 - 2029) 4.80 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration High

Major Players

Pharmaceutical Dextran (Glucose) Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Pharmaceutical Dextran (Glucose) Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Pharmaceutical Dextran (Glucose) Market Analysis

The Pharmaceutical Dextran Market size is estimated at USD 231.20 million in 2024, and is expected to reach USD 292.80 million by 2029, growing at a CAGR of 4.80% during the forecast period (2024-2029).

Dextran, a homopolysaccharide comprising glucose molecules linked by glycosidic bonds, boasts a structure that can be tailored by incorporating diverse hydrophobic molecules. Known for its water solubility, biocompatibility, and biodegradability, dextran and its derivatives are pivotal in drug delivery systems. Notably, they excel in preparing NPs for drug delivery, showing promise in enhancing the oral delivery of active drugs.

Companies are adopting strategic measures such as collaborations and regional expansions to bolster their market presence. For instance, in May 2024, DKSH’s Business Unit Performance Materials, a prominent distributor of specialty chemicals, announced its support for TdB Labs. This collaboration aims to bolster TdB Labs’ pharmaceutical business in India, focusing on dextran derivatives and other polysaccharides tailored for pharmaceutical and diagnostic applications.

The expanding applications of dextran will propel its market share in the coming years. For instance, an article by the National Center for Biotechnology Information in July 2023 highlighted the rising interest in dextran and its derivatives for breast cancer therapy. Researchers have successfully boosted the efficacy of anticancer agents by conjugating dextran with antitumor medications.

Dextran's versatility and expanding applications underscore its significant potential in the pharmaceutical industry. Strategic collaborations and ongoing research further enhance its market prospects, particularly in drug delivery and cancer therapy.

Pharmaceutical Dextran (Glucose) Market Trends

Dextran 40 Holds Significant Market Share in the Pharmaceutical Industry

Dextran 40 is experiencing significant growth due to its diverse pharmaceutical industry applications. Dextran 40, a pharmaceutical-grade ingredient, is an excipient in the final formulations of drug products. It is also pivotal in producing injection and infusion solutions.

Dextran 40, a key segment in medical applications, bolsters segmental growth with its unique benefits. Primarily, it acts as a plasma volume expander, restoring blood volume for patients grappling with hypovolemia or shock. By lowering blood viscosity and thwarting red blood cell clumping, dextran 40 enhances microcirculation and boosts tissue perfusion. Moreover, its antithrombotic nature mitigates clotting risks and doubles as a potent drug carrier, amplifying medication distribution and efficacy. Given its broad medical applicability and stellar safety record, dextran 40 is an indispensable asset in clinical setups.

The rising applications of dextran 40 are set to drive market growth in the coming years. Pharmacosmos A/S is a leading manufacturer that ensures its dextran 40 products meet strict pharmacopoeial standards, including the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), and the Japanese Pharmacopoeia (JP). The products are available for lyophilization, oral applications, cryopreservation, organ preservation, and as a blood volume expander. Also, dextran 40 is widely used across various molecular weights. It acts as a colloid and expands plasma volume osmotically, replenishing blood plasma lost during severe hemorrhages. Its systemic effects enhance cardiac output and blood flow, thereby facilitating the circulation of red blood cells to microvasculature in vital organs.

Moreover, the market for dextran 40 is further bolstered by its expanding applications. In January 2024, an article published by Verdict Media Limited emphasized the progression of several stem-cell therapies from preclinical stages to advanced clinical trials. Effective treatments rely on developing resilient formulations, particularly those utilizing mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs). These formulations play a critical role in maintaining cell viability throughout the treatment's lifecycle, from cryopreservation and storage to handling, shipment, and eventual reconstitution before administration to patients. Many of these formulations prominently include dextran 40, often in conjunction with other vital components.

Dextran 40's growing applications and stringent quality standards drive its market dominance. As the pharmaceutical industry continues to innovate, particularly in stem-cell therapies, the demand for dextran 40 is expected to rise, solidifying its significant market share in the coming years.

Pharmaceutical Dextran (Glucose) Market: Number of Stem Cell Therapy Clinical Trials (in Units), Global, As of June 2024

North America is Expected to Hold a Dominating Market Share During the Forecast Period

The pharmaceutical dextran (glucose) market is set to witness substantial growth over the coming years, with North America expected to hold a dominant market share. Key manufacturers, growing adoption in diverse industries, and a robust consumer base underpin the region's significant presence in the dextran market.

Companies are bolstering their market positions through strategic acquisitions and collaborations. For instance, in August 2023, Biospectra Inc. and BiaSpestra Canada Ltd acquired a majority stake in Polydex Pharmaceuticals Limited. This strategic move provided Biospectra Inc. with direct access to Polydex’s products, including dextran and derivative products, aiding in the expansion and modernization of the GMP (good manufacturing practice) dextran products portfolio. This acquisition also included additional manufacturing capacity and patents, which are expected to enhance production capabilities and product innovation.

Similarly, the burgeoning development of stem cell-based solutions in North America is anticipated to boost the demand for dextran significantly. In April 2023, in the United States, Gamida Cell Ltd reported the FDA's approval for Omisirge (emidubicel-enlv), allogeneic cell therapy. Notably, this therapy incorporates dextran 40 in its cryopreservation process.

The FDA-approved allogeneic cord blood hematopoietic progenitor cell therapy also employs a similar cryopreservation method involving dextran. These advancements highlight the critical role of dextran in cutting-edge medical therapies and its expanding application scope.

North America is poised to lead the pharmaceutical dextran market owing to strategic business moves and enhanced applications, broadening its utility. North America's significant manufacturing infrastructure, bolstered by a thriving consumer base and continuous advancements in dextran applications, solidifies its standing as a key industry player. With the rising demand for dextran, fueled by its diverse applications and crucial medical functions, North America is set to retain and potentially enhance its market dominance in the future.

Pharmaceutical Dextran (Glucose) Market: Market CAGR (%), By Region, Global, 2023

Pharmaceutical Dextran (Glucose) Industry Overview

The pharmaceutical dextran (glucose) market is consolidated and consists of a selective number of major players. Both regional and global players in the healthcare industry are increasingly turning to vertical collaboration as a key strategy to bolster their market positions. As emerging nations witness a surge in the adoption of digital health technologies, they are transforming into battlegrounds for intense competition. Some market players in the pharmaceutical dextran (glucose) market are Pharmacosmos A/S, Polydex Pharmaceuticals Limited, Meito Sangyo Co. Ltd, Jinyang Pharm, and pK Chemicals A/S.

Pharmaceutical Dextran (Glucose) Market Leaders

  1. PHARMACOSMOS A/S

  2. Polydex Pharmaceuticals Limited.

  3. Meito Sangyo Co., Ltd. 

  4. Jinyang Pharm

  5. pK Chemicals A/S

*Disclaimer: Major Players sorted in no particular order

Pharmaceutical Dextran (Glucose) Market Concentration
Need More Details on Market Players and Competitors?
Download PDF

Pharmaceutical Dextran (Glucose) Market News

  • January 2024: Ildong Pharmaceutical announced a strategic move by signing an eye drop co-promotion agreement with Hanlim Pharm. This collaboration aims to facilitate Ildong's entry into the OTC (over-the-counter) segment of the ophthalmology market. The agreement spotlights Numaren Eye Drops, a hypromellose-dextran formulation designed to address dry eyes and tear production deficiencies.
  • August 2023: The Drug Administration of Vietnam and the Ministry of Health licensed the import of 17,010 bags of dextran infusion. These imports were specifically for infirmaries lacking circulation registration, which aligned with prevailing regulations. The Ministry of Health emphasized dextran's significance as a high molecular weight solution, particularly in treating patients with dengue shock syndrome.

Pharmaceutical Dextran (Glucose) Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Adoption of Dextran In Numerous Pharmaceutical Applications

      2. 4.2.2 Growing Demand For Blood Plasma Substitutes

    3. 4.3 Market Restraints

      1. 4.3.1 High Production Costs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 5.1 By Power Type

      1. 5.1.1 Dextran 20

      2. 5.1.2 Dextran 40

      3. 5.1.3 Dextran 60

      4. 5.1.4 Dextran 70

      5. 5.1.5 Other Power Types

    2. 5.2 By Application

      1. 5.2.1 Vaccines

      2. 5.2.2 Eye Care

      3. 5.2.3 Protein Stabilization

      4. 5.2.4 Cryopreservation

      5. 5.2.5 Oral Application

      6. 5.2.6 Other Applications

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Rest of World

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 PHARMACOSMOS A/S

      2. 6.1.2 Polydex Pharmaceuticals Limited

      3. 6.1.3 Meito Sangyo Co. Ltd

      4. 6.1.4 Jinyang Pharm

      5. 6.1.5 pK Chemicals A/S

      6. 6.1.6 Pfizer Inc.

      7. 6.1.7 Merck KGaA

      8. 6.1.8 Central Drug House

      9. 6.1.9 Otto Chemie Pvt. Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments.
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Pharmaceutical Dextran (Glucose) Industry Segmentation

Dextran, a viscous polysaccharide produced through bacterial action on sucrose, is widely utilized in various applications, including confections, lacquers, and, most notably, medicine, as an extender for blood plasma.

The pharmaceutical dextran (glucose) market is segmented into power type, application, and geography. By power type, the market is segmented into dextran 20, dextran 40, dextran 60, dextran 70, and other power types. By application, the market is segmented into vaccines, eye care, protein stabilization, cryopreservation, oral application, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. For each segment, the market sizing and forecasts are based on revenue (USD).

By Power Type
Dextran 20
Dextran 40
Dextran 60
Dextran 70
Other Power Types
By Application
Vaccines
Eye Care
Protein Stabilization
Cryopreservation
Oral Application
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of World
Need A Different Region Or Segment?
Customize Now

Pharmaceutical Dextran (Glucose) Market Research FAQs

The Pharmaceutical Dextran Market size is expected to reach USD 231.20 million in 2024 and grow at a CAGR of 4.80% to reach USD 292.80 million by 2029.

In 2024, the Pharmaceutical Dextran Market size is expected to reach USD 231.20 million.

PHARMACOSMOS A/S, Polydex Pharmaceuticals Limited., Meito Sangyo Co., Ltd., Jinyang Pharm and pK Chemicals A/S are the major companies operating in the Pharmaceutical Dextran Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Pharmaceutical Dextran Market.

In 2023, the Pharmaceutical Dextran Market size was estimated at USD 220.10 million. The report covers the Pharmaceutical Dextran Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Pharmaceutical Dextran Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Pharmaceutical Dextran (Glucose) Industry Report

Statistics for the 2024 Pharmaceutical Dextran (Glucose) market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Pharmaceutical Dextran (Glucose) analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Pharmaceutical Dextran (glucose) Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)